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Waist-hip ratio (WHR) is a measure of body fat distribution and a predictor of metabolic 
consequences independent of overall adiposity. WHR is heritable, but few genetic variants 
influencing this trait have been identified. We conducted a meta-analysis of 32 genome-wide 
association studies for WHR adjusted for body-mass-index (up to 77,167 participants), following 
up 16 loci in an additional 29 studies (up to 113,636 subjects). We identified 13 novel loci in or 
near RSPO3, VEGFA, TBX15-WARS2, NFE2L3, GRB14, DNM3-PIGC, ITPR2-SSPN, LY86, 
HOXC13, ADAMTS9, ZNRF3-KREMEN1, NISCH-STAB1, and CPEB4 (P 1.9 × 10−9 to 1.8 × 
10−40), and the known signal at LYPLAL1. Seven of these loci exhibited marked sexual 
dimorphism, all with a stronger effect on WHR in women than men (P for sex-difference 1.9 × 
10−3 to 1.2 × 10−13). These findings provide evidence for multiple loci that modulate body fat 
distribution, independent of overall adiposity, and reveal powerful gene-by-sex interactions.
Keywords
genome-wide association; waist-hip-ratio; body fat distribution; central obesity; meta-analysis; 
genetics; visceral adipose tissue; metabolism; body composition; Expression Quantitative Trait 
Loci; sex difference
Central obesity and body fat distribution, as measured by waist circumference (WC) and 
waist-hip-ratio (WHR), are associated with individual risk of type 2 diabetes (T2D)1,2 and 
coronary heart disease3, and with all-cause mortality4. These effects are independent of 
overall adiposity as measured by body mass index (BMI). WHR is of particular interest as a 
measure of body fat distribution, since it integrates the adverse metabolic risk associated 
with increasing WC with the more protective role of gluteal fat deposition with respect to 
diabetes, hypertension, and dyslipidemia5,6.
There is abundant evidence that body fat distribution is influenced by genetic loci distinct 
from those regulating BMI and overall adiposity. First, even after accounting for BMI, 
individual variation in WHR is heritable7,8, with estimates ranging from 22–61%7–10. 
Second, the striking abnormalities of regional fat deposition associated with lipodystrophic 
syndromes demonstrate that genetic variation can have dramatic effects on the development 
and maintenance of specific fat depots11,12. Third, in a previous genome-wide association 
analysis, we identified a locus near LYPLAL1 strongly associated with WHR independent of 
any effects on BMI13, providing proof-of-principle for the genetic control of body fat 
distribution, distinct from that of overall adiposity.
Within the GIANT (Genetic Investigation of Anthropometric Traits) consortium, we 
performed a large-scale meta-analysis of genome-wide association (GWA) studies 
informative for WHR, using adjustment for BMI to focus discovery towards genetic loci 
associated with body fat distribution rather than overall adiposity14–16.
RESULTS
Genome-wide significant association of WHR with 14 SNPs
We conducted a two-stage study among individuals of European descent (Supplementary 
Table 1 and Online Methods). In the discovery stage, up to 2,850,269 imputed and 
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genotyped single nucleotide polymorphisms (SNPs) were examined in 32 GWA studies 
comprising up to 77,167 participants informative for anthropometric measures of body fat 
distribution. We performed a fixed-effects meta-analysis of WHR, employing study-specific 
linear regression adjusted for BMI and age, stratified by gender, and using an additive 
genetic model. After genomic control adjustment per study and in the meta-analysis, these 
analyses revealed a substantial excess of low p-values (Figure 1 a, b).
We selected SNPs representing the top 16 independent (> 1 Mb distance) regions of 
association (discovery P < 1.4 × 10−6, Table 1) and evaluated them in 29 additional, 
independent studies (up to 113,636 individuals) using a mixture of in silico data and de novo 
genotyping. In these follow-up studies, 14 of the 16 showed strong directionally-consistent 
evidence for replication (P < 1.0 × 10−3) and ten reached genome-wide significance (P < 5.0 
× 10−8). Joint analysis of the discovery and follow-up results revealed genome-wide 
significant associations for 14 signals (P between 1.9 × 10−9 and 1.8 × 10−40, Table 1).
Between-study heterogeneity was low (I2 < 30%) for all but two signals (GRB14 and 
LYPLAL1, see Supplementary Note) and all 14 associations remained genome-wide 
significant in a random-effects meta-analysis (Supplementary Table 2).
One of these SNPs, rs4846567, is in linkage disequilibrium (LD, r2 = 0.64, D’ = 0.84; 
HapMap CEU) with the previously reported WHR-associated variant (rs2605100) near the 
LYPLAL1 gene13. The remaining 13 loci were in or near genes not previously associated 
with WHR or other measures of adiposity: RSPO3, VEGFA, TBX15-WARS2, NFE2L3, 
GRB14, DNM3-PIGC, ITPR2-SSPN, LY86, HOXC13, ADAMTS9, ZNRF3-KREMEN1, 
NISCH-STAB1, and CPEB4 (Figure 2). These 14 loci explain 1.03% of the variance in WHR 
(after adjustment for BMI, age, and sex), with each locus contributing from 0.02% (ZNRF3-
KREMEN1) to 0.14% (RSPO3) based on effect estimates in the follow-up stage.
Sexual dimorphism at several of the WHR loci
Given the known sexual dimorphism of WHR and evidence from variance decomposition 
studies that this reflects sex-specific genetic effects17, we performed sex-specific meta-
analyses for the 14 WHR associated SNPs. These analyses included up to 108,979 women 
(42,735 discovery, 66,244 follow-up) or 82,483 men (34,601 discovery, 47,882 follow-up). 
In joint analysis of discovery and follow-up data, 12 of the 14 SNPs reached genome-wide 
significance in women, but only 3 in men (Table 2). At all but one locus (TBX15-WARS2), 
effect-size estimates were numerically greater in women. At seven of the loci (those near 
RSPO3, VEGFA, GRB14, LYPLAL1, HOXC13, ITPR2-SSPN and ADAMTS9), there were 
marked differences in sex-specific beta-coefficients (P ranging from 1.9 × 10−3 to 1.2 × 
10−13). All loci displayed consistent patterns of sex-specific differences in both discovery 
and follow-up studies (Table 2). These 14 loci explain 1.34% of the variance in WHR (after 
adjustment for BMI and age) in women, but only 0.46% in men.
Association with other anthropometric measures
By focusing on WHR after adjustment for BMI, our goal was to detect effects on body fat 
distribution independent of those influencing overall adiposity. As expected, we found very 
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little evidence that known BMI-associated variants were detected in our WHR analysis. Of 
the 10 loci identified shown to be associated with BMI in previous genome-wide association 
studies 14,15,18, only two showed nominally significant (P < 0.05) associations for BMI-
adjusted WHR in the discovery analysis (FTO: rs805013614, P = 0.03, N = 77,074; 
TMEM18: rs654823815, P = 3.0 × 10−3, N = 77,016).
We also tested the 14 WHR-associated SNPs for their effect on BMI using data from up to 
242,530 participants available from the GIANT consortium (including most of the studies 
available for WHR association). Of the 14 WHR loci, four (near TBX15-WARS2, CPEB4, 
LYPLAL1 and GRB14) also showed evidence of association with BMI (4.1 × 10−3 ≤ P ≤ 
3.2×10−6) with the WHR-increasing allele associated with decreased BMI (Supplementary 
Table 3). When adding an interaction term of SNP and BMI into the model, we observed 
that BMI modified the WHR association at the LY86 locus (P for interaction = 9.5 × 10−5) 
with a larger WHR effect among the obese compared to the non-obese (see Supplementary 
Note).
To determine whether the WHR-associated signals exert their effects primarily through an 
effect on waist (WC) or hip circumference (HIP), we performed meta-analyses for these 
specific phenotypes in the discovery and follow-up studies (Supplementary Table 1 and 3). 
Overall, we observed stronger associations for HIP than for WC. Effect-size estimates were 
numerically greater for HIP than for WC at eleven of the 14 loci, and there were nominal 
associations (P < 0.05) with HIP for twelve of the WHR-associated loci but only four 
associations with WC. In both sexes, the WHR-associated loci displaying nominal 
association with HIP always featured the WHR-increasing allele associated with reduced 
HIP. In contrast, we observed sexual dimorphism in the pattern of WC associations. In 
women, the WHR-increasing allele at all 14 loci was associated with increased WC, whereas 
this was only true for 6 of these loci in men (Figure 3). At GRB14, for example, the WHR-
increasing allele was associated with increased WC in women (P = 3.6 × 10−4) but 
decreased WC in men (P = 6.8 × 10−3). These differences in the relationships between WC, 
HIP and WHR underlie some of the sexual dimorphism in the patterns of WHR association.
Enrichment of association with metabolic traits
We evaluated the 14 WHR-associated loci for their relationships with related metabolic 
traits using GWA data provided by trait-specific consortia19–21 as well as our de novo 
genotyped follow-up studies. As expected, given the sample overlap between this GWA data 
with our WHR GWA data as well as known trait correlations (Supplementary Table 4), we 
observed directionally consistent enrichment of associations (P < 0.05) between the 14 
WHR-associated alleles and increased triglycerides, LDL-cholesterol, fasting insulin, and 
HOMA-derived measures of insulin resistance (binomial P from 3.2 × 10−4 to 1.8 × 10−8; 
Table 3 and Supplementary Table 5a). For example, the WHR-increasing allele at GRB14 
shows strong associations with increased triglycerides (P = 7.4 × 10−9), fasting insulin levels 
(P = 5.0 × 10−6) and insulin resistance (P = 1.9 × 10−6). Eleven of 14 WHR-associated loci 
showed directionally consistent associations with T2D, three of these (ADAMTS9, NISCH-
STAB1, and ITPR2-SSPN) reaching nominal significance (P < 0.05) (Table 3 and 
Supplementary Table 5a,b). Because the association signals for correlated traits in this 
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analysis are vulnerable to overestimation given the overlap in GWAS samples examined, we 
repeated these analyses restricted to our de novo genotyped follow-up studies. Although this 
also resulted in lower sample size, similar patterns of enrichment were still observed 
(Supplementary Table 5c).
Pathway analysis of the WHR-associated loci and potential biological role
To identify potential functional connections and pathway relationships between genes 
mapping at the WHR-associated loci, we focused on the 95 genes located in a 2 Mb interval 
centered around each of the 48 independent SNPs that attained a P < 1.0 × 10−5 in the WHR 
discovery studies.
First, we performed a survey of the published literature using GRAIL22, to search for 
connectivity between the genes and specific keywords that describe these functional 
connections (see Online Methods). Although there was no evidence, after correcting for 
multiple testing, that the connectivity between these genes was greater than chance, we 
identified 8 genes with nominal significance (P < 0.05) for potential functional connectivity 
(PLXND, HOXC10, TBX15, RSPO3, HOXC4, HOXC6, KREMEN1 and HOXC11). The 
keywords associated with these connections included “vegf”, “homeobox”, “patterning”, 
“mesenchyme”, “embryonic”, “development” and “angiogenesis”.
Additionally, we performed pathway analyses using the PANTHER database23 based on the 
same set of 95 genes (Online methods and Supplementary Note). This analysis generated 
some evidence for over-representation of “developmental processes” (P = 5.8 × 10−8) and 
“mRNA transcription regulation” (P = 2.7 × 10−6), but neither retained nominal significance 
after adjustment for bias (e.g. due to non-random SNP coverage in relation to genes) and the 
number of biological processes tested (Supplementary Note, Supplementary Table 6).
Finally, we examined the described functional roles of some of the most compelling 
candidates based on either proximity to the signal or other analyses described in this paper. 
These uncovered possible roles in adipocyte development (TBX15), pattern formation during 
embryonic development (HOXC13), angiogenesis (VEGFA, RSPO3, STAB1), Wnt/beta-
catenin signaling (RSPO3, KREMEN1), insulin signaling (ADAMTS9, GRB14, NISCH), 
lipase activity (LYPLAL1), lipid biosynthesis (PIGC) and intracellular calcium signaling 
(ITPR2) (see Supplementary Note for details).
Evaluation of copy number variants (CNVs) and nonsynonymous changes
Both common and rare CNVs have been reported to be associated with overall 
adiposity14,15,24,25, but the impact of CNVs on fat distribution has not been evaluated 
previously. To examine the potential contribution of common CNVs to variation in WHR, 
we looked for evidence of association in our GWA discovery meta-analysis, using a set of 
6,018 CNV-tagging SNPs, which collectively capture >40% of common CNVs >1 kb 26,27 
(Online Methods, Supplementary Note).
One CNV-tagging SNP (rs1294421, LY86) was observed amongst our 14 WHR-associated 
loci. This SNP is in strong LD (r2 = 0.98) with a 2,832 bp duplication variant 
(CNVR2760.1)27, located 12 kb from an expressed sequence tag (BC039678) and 87 kb 
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from LY86, such that the duplication allele is associated with reduced WHR. The duplicated 
region consists entirely of noncoding sequence but includes part of a predicted enhancer 
sequence (E.5552.1)28.
To identify other putatively causal variants in our associated regions, we searched for non-
synonymous coding SNPs in strong LD (r2>0.7) with the most strongly associated SNPs at 
each locus using data from the HapMap (Build 21) and 1000 Genomes Project (April and 
August 2009 releases). In this search, one lead SNP (rs6784615, at the NISCH-STAB1 locus) 
was correlated with non-synonymous changes in two nearby genes, DNAH1 (Val441Leu, 
Arg1285Trp and Arg3809Cys) and GLYCTK (Leu170Val). Fine-mapping and functional 
studies will be required to determine whether the DNAH1 or GLYCTK SNPs or the LY86 
CNV are causal for the WHR-associations at these loci.
Evaluation of effect of the WHR associations on expression in relevant tissues
Expression-QTL (eQTL) data can implicate regional transcripts that mediate trait-
associations, and we therefore examined the 14 WHR-associated loci using eQTL data from 
human subcutaneous adipose tissue (SAT)29 (two separate sample sets, N=610 and N=603), 
omental fat30 (N=740), liver30 (N=518), blood29 (N=745), and lymphocytes31 (N=830) 
(Online methods, Supplementary Note).
At six of the loci, the WHR-associated SNP was either the strongest SNP associated with 
significant (P < 1.0 × 10−5) expression of a local (within 1 Mb) gene transcript or explained 
the majority of the association between the most significant eQTL SNP and the gene 
transcript in conditional analyses (adjusted P > 0.05; Table 4). For example, the WHR-
associated SNP rs1011731 (near DNM3-PIGC) was strongly-associated with expression of 
PIGC in lymphocytes (P = 5.9 × 10−10); furthermore, rs1011731 is in high LD (r2 = 1.00, D’ 
= 1.00, HapMap CEU) with the SNP with the strongest effect on PIGC expression 
(rs991790), and this cis-eQTL association is abolished by conditioning on rs1011731. These 
analyses therefore indicate that these two signals are coincident and that PIGC is a strong 
candidate for mediating the WHR-association at rs1011731. We found similar evidence for 
coincidence of the WHR signal with expression for rs984222 (TBX15 in omental fat), 
rs1055144 (expressed sequence tag AA553656 in SAT), rs10195252 (GRB14 in SAT), 
rs4823006 (ZNRF3 in SAT and omental fat), and rs6784615 (STAB1 in blood)(Table 4). 
Taken together, the overlap between trait association and gene expression at these loci 
suggests that the WHR associations are driven through altered expression of PIGC, TBX15, 
AA553656, GRB1, ZNRF3 and STAB1.
Differential RNA expression of gluteal compared to abdominal fat tissue
To determine whether genes within the WHR-associated loci showed evidence of 
differential transcription in distinct fat-depots, we compared expression levels in gluteal or 
abdominal SAT in 49 individuals. We focused on the 15 genes with the strongest credentials 
for causal involvement (on the basis of proximity to the lead SNP and/or other biological or 
functional data: Table 1) for which expression data were available. Five of these (RSPO3, 
TBX15, ITPR2, WARS2 and STAB1) were differentially expressed between the two tissues 
(F-test, corrected for false discovery rate across the 15 expressed genes, P < 0.05; 
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Supplementary Table 7). This supported the hypothesis that, at some loci at least, the 
association with WHR reflects depot-specific differences in expression patterns.
DISCUSSION
Overall, our findings demonstrate that the genetic regulation of body fat distribution 
involves loci and processes that are largely distinct from those that influence BMI and risk 
of obesity. This finding is consistent with the evidence that WHR displays substantial 
heritability even after adjustment for BMI. The loci that emerge from this study display no 
overlap with those shown to be associated with BMI, either in previous reports14,15,16 or in 
the expanded meta-analysis recently completed by the GIANT consortium32.
Another point of distinction between our findings and those for BMI relates to the evidence 
for sexual dimorphism that we observed at several of the WHR-associated loci. Sex 
differences in the regulation of body fat distribution have long been acknowledged without a 
clear understanding of the underlying molecular mechanisms. These differences become 
apparent during puberty and are generally attributed to the influence of sex hormones33. 
Consistent with our findings, variance decomposition studies have shown that the genetic 
contribution to the overall variance in WHR, waist or hip circumference is greater in 
women17. While there is some evidence for loci with differential sex effects influencing 
lipids34, uric acid levels35 and risk of schizophrenia36, we are unaware of prior reports 
indicating such strong enrichment of female-specific associations for any other phenotype, 
including BMI32.
The primary objective of genetic discovery efforts is to characterize the specific mechanisms 
involved in the regulation of the trait of interest. Despite the considerable challenges 
associated with moving from common variant association signals to definition of the causal 
alleles and pathways, we have identified strong candidates at several of the loci. For 
example, the cis-eQTL data implicate GRB14 as a compelling candidate for the WHR-
association on chromosome 2, and we were able to show that the same GRB14 variants are 
also associated with triglyceride and insulin levels, consistent with previous association of 
this locus with HDL-cholesterol 37. These inferences about the role of GRB14 are supported 
by evidence that Grb14-deficient mice exhibit improved glucose homeostasis despite lower 
circulating insulin levels, and enhanced insulin signaling in liver and skeletal muscle38. The 
signal near ADAMTS9 overlaps a previously-reported T2D locus39, and the lead SNP for 
WHR in our study is identical to the SNP displaying the strongest T2D association in an 
expanded T2D meta-analysis40. Given evidence that ADAMTS9 T2D-risk alleles are 
associated with insulin resistance in peripheral tissues41, these findings are consistent with a 
primary effect of ADAMTS9 variants on body fat distribution. At the chromosome 6 locus, 
VEGFA is the most apparent biological candidate, given the presumed role of VEGFA as a 
mediator of adipogenesis42 and evidence that serum levels of VEGFA are correlated with 
obesity43,44. Finally, at the TBX15-WARS2 locus, TBX15 emerges as the strongest 
candidate based on the cis-eQTL data in omental fat, marked depot-specific differences in 
adipose tissue expression in mice and humans, and associations between TBX15 expression 
in visceral fat and WHR45,46.
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Our efforts to use pathway- and literature-mining approaches to look for functional 
enrichment of the genes mapping to associated regions met with only limited success, but 
did provide some support for overrepresentation of developmental processes. 
Developmental genes have been implicated in fat accumulation and distribution45,46, and 
recent evidence supports a link between developmental genes and body fat distribution, 
including HOXC1347 and TBX1545,48. Developmental genes may in part determine the 
adipocyte-specific expression patterns that have been observed in different fat depots45. 
Taken together, our findings point to a set of genes influencing body fat distribution that 
have their principal effects in adipose tissue. This is in contrast to the predominantly central 
(hypothalamic) processes that are involved in the regulation of body mass index and overall 
adiposity49.
By providing novel insights into the regulation of body fat distribution, the present study 
raises a number of issues for future investigation. From the genetic perspective, re-
sequencing, dense-array genotyping and fine-mapping approaches will be required to 
characterize causal variants at the loci we have identified, and to support further discoveries 
that may account for the substantial proportion of genetic variance unexplained by our 
findings. From the clinical perspective, it will be important to explore the relationship of 
these variants to more refined measures of body fat distribution derived from detailed 
imaging studies, to use the variants identified to characterise the causal relationships 
between body fat distribution and related metabolic and cardiovascular traits, and to explore 
ethnic differences in patterns of body fat distribution. Efforts to tackle overall obesity 
through therapeutic or lifestyle-based modulation of overall energy balance have proved 
extremely challenging to implement, and the manipulation of processes associated with 
more beneficial patterns of fat distribution offers an alternative perspective for future drug 
discovery.
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BMI Body-mass-index
WC waist circumference
WHR waist-hip ratio
HIP hip circumference
GWA genome-wide association
SNP single-nucleotide polymorphism
LD linkage disequilibrium
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Figure 1. Genome-wide association analyses for WHR in discovery studies
A. Manhattan plot shows results of the WHR association meta-analysis in discovery studies 
(P on the y-axis and SNP genomic position on the x-axis). Colored genomic loci indicate 
significant association (P < 5 × 10−8) detected previously (blue)13, in our GWA stage (red), 
and after the meta-analysis combining GWA and follow-up studies (orange). Two loci tested 
in the follow-up stage did not achieve genome-wide significance (green).
B. Quantile-quantile (QQ) plot of SNPs for the discovery meta-analysis of WHR (black) and 
after removing SNPs within 1 Mb of either the recently reported LYPLAL1 signal (blue) or 
the 14 significant associations (green). The grey area represents the 95% confidence interval 
around the test statistic under the null distribution.
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Figure 2. Regional plots of 14 loci with genome-wide significant association
SNP association with WHR in meta-analysis of discovery studies for 14 loci (−log10 P on 
the y-axis and SNP genomic position on the x-axis). In each panel, an index SNP is denoted 
with a purple diamond and plotted using the P attained across discovery and follow-up data 
(Table 1). Estimated recombination rates are plotted in blue. SNPs are colored to reflect LD 
with the index SNP (pair-wise r2 values from HapMap CEU). Gene and microRNA 
annotations are from the UCSC genome browser.
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Figure 3. Association of the 14 WHR loci with waist and hip circumference
Beta-coefficients for waist circumference (WC, x-axis) and hip circumference (HIP, y-axis) 
in women and men derived from the joint discovery and follow-up analysis. P for WC and 
HIP are represented by color. In men, grey gene labels refer to those SNPs that were not 
significant in the male-specific WHR analysis. More details can be found in Supplementary 
Table 3.
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Figure 4. 
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